1313275-26-1

Basic information

• Product Name: C₄₇H₆₄O₁₃Si₂
• Synonyms: C₄₇H₆₄O₁₃Si₂
• CAS NO: 1313275-26-1
• Molecular Weight: 893.188
• Mol File: 1313275-26-1.mol

Chemical Properties

• CAS DataBase Reference: C₄₇H₆₄O₁₃Si₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₄₇H₆₄O₁₃Si₂(1313275-26-1)
• EPA Substance Registry System: C₄₇H₆₄O₁₃Si₂(1313275-26-1)

Safety Data

• Hazardous Substances Data: 1313275-26-1(Hazardous Substances Data)

Upstream product

• 164264-14-6 (3S)-3-[(1,1-Dimethylethyl)dimethylsilyloxy]-oxolan-2-one 
• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 50-85-1 2-hydroxy-p-toluic acid 
• 18395-90-9 Di-tert-butyldichlorosilane 
• 1313275-61-4 C₃₁H₃₈O₈Si 
• 1313275-59-0 C₃₃H₄₂O₉Si 
• 1313275-22-7 (2S,4S)-2-(tert-butyldimethylsilyloxy)-N-methoxy-4[(4-methoxybenzyl)oxy]-N-methylhex-5-enamide 
• 1335208-31-5 (2S,4S)-2-(tert-butyldimethylsilyloxy)-4-hydroxy-N-methoxy-N-methylhex-5-enamide 
• 1313275-21-6 (2S)-2-(tert-butyldimethylsilyloxy)-N-methoxy-N-methyl-4-oxobutanamide 
• 1313275-47-6 (2S)-2-(tert-butyldimethylsilyloxy)-4-hydroxy-N-methoxy-N-methylbutanamide 
• 1313275-14-7 2-(allyloxy)-N,N-diethyl-4-methylbenzamide 
• 1313275-02-3 (S)-1-diazo-3-epoxy-5,5-dimethoxypenta-2,4-dione 
• 1313275-00-1 C₃₉H₅₄O₈Si₂ 
• 1313275-39-6 (2R,3S)-diazo-3-epoxy-4-hydroxy-5,5-dimethoxypenta-2-one 

Relevant articles and documents

A multiply convergent platform for the synthesis of trioxacarcins

Many first-line cancer drugs are natural products or are derived from them by chemical modification. The trioxacarcins are an emerging class of molecules of microbial origin with potent antiproliferative effects, which may derive from their ability to covalently modify duplex DNA. All trioxacarcins appear to be derivatives of a nonglycosylated natural product known as DC-45-A2. To explore the potential of the trioxacarcins for the development of smallmolecule drugs and probes, we have designed a synthetic strategy toward the trioxacarcin scaffold that enables access to both the natural trioxacarcins and nonnatural structural variants. Here, we report a synthetic route to DC-45-A2 froma differentially protected precursor, which in turn is assembled in just six steps from three components of similar structural complexity. The brevity of the sequence arises from strict adherence to a plan in which strategic bond-pair constructions are staged at or near the end of the synthetic route.

TRIOXACARCINS AND USES THEREOF

The present invention relates to trioxacarcin compounds of the formula: (I) or pharmaceutically acceptable forms thereof; wherein R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein. The present invention also provides processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; and methods of use and treatment.